Ono Pharmaceutical CoTSE:4528 -0.86%89 PB Ratio is 1.34 as of Jul. 13, 2026, which is 36% below its 10-year median of 2.10. GuruFocus rates TSE:4528 with a GF Score™ of 89/100 and a GF Value™ of 円2,240.58 (Fairly Valued). The stock has 4 warning signs investors should review. Among 925 Drug Manufacturers companies, Ono Pharmaceutical Co ranks better than 65.3% on this metric.
The historical rank and industry rank for Ono Pharmaceutical Co's PB Ratio or its related term are showing as below:
TSE:4528'
s PB Ratio Range Over the Past 10 Years
Min: 0.88 Med: 2.1 Max: 4.45
Current: 1.34
During the past 13 years, Ono Pharmaceutical Co's highest PB Ratio was 4.45. The lowest was 0.88. And the median was 2.10.
TSE:4528's PB Ratio is ranked better than 65.3% of 925
companies
in the Drug Manufacturers industry
Industry Median: 1.91
vs TSE:4528: 1.34
During the past 12 months, Ono Pharmaceutical Co's average Book Value Per Share Growth Rate was 8.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 6.00% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 7.50% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 7.60% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Ono Pharmaceutical Co was 10.50% per year. The lowest was -4.30% per year. And the median was 4.80% per year.
Back to Basics: PB Ratio
Ono Pharmaceutical Co (TSE:4528) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Ono Pharmaceutical Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ono Pharmaceutical Co PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ono Pharmaceutical Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Ono Pharmaceutical Co's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Ono Pharmaceutical Co (TSE:4528) has a PB Ratio of 1.34 as of Jul. 13, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Ono Pharmaceutical Co and its competitors. This is 36% below median its historical median of 2.10. Over the past decade, Ono Pharmaceutical Co's PB Ratio has ranged from 0.88 to 4.45. According to the industry distribution chart, Ono Pharmaceutical Co ranks #321 out of 925 companies in the Drug Manufacturers industry, placing it in the top 34.7%.
Is Ono Pharmaceutical Co's PB Ratio too high?
Ono Pharmaceutical Co's current PB Ratio of 1.34 is 36% below median its 10-year median of 2.10. Over the past 10 years, this metric has ranged from a low of 0.88 to a high of 4.45. The Drug Manufacturers industry median PB Ratio is 1.91. Ono Pharmaceutical Co's value of 1.34 is 29.8% below this industry median. Based on the distribution chart, Ono Pharmaceutical Co ranks #321 out of 925 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Ono Pharmaceutical Co has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ono Pharmaceutical Co's PB Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Ono Pharmaceutical Co ranks #321 out of 925 companies for PB Ratio. This puts Ono Pharmaceutical Co in the upper half of its industry. The industry median PB Ratio is 1.91. Ono Pharmaceutical Co's value of 1.34 is 29.8% below this benchmark. Historically, Ono Pharmaceutical Co's own PB Ratio has ranged from 0.88 to 4.45 over the past decade. While the company's 10-year median is 2.10 vs. the industry median of 1.91, Ono Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.91, based on 925 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ono Pharmaceutical Co's current PB Ratio of 1.34 is 29.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Ono Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ono Pharmaceutical Co's current PB Ratio is 1.34, which is 36% below median its own 10-year median of 2.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ono Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Ono Pharmaceutical Co (TSE:4528) is currently considered Fairly Valued. The stock's GF Value™ is 円2,240.58, compared to a current price of 円2,428.00 — trading 8.4% above its estimated fair value. The current PB Ratio is 1.34, which is 36% below median its 10-year median of 2.10 and 29.8% below the Drug Manufacturers industry median of 1.91. Ono Pharmaceutical Co's overall GF Score™ is 89/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Ono Pharmaceutical Co (TSE:4528), the current PB Ratio is 1.34 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ono Pharmaceutical Co (TSE:4528) Overvalued in 2026?
Based on GuruFocus' analysis, Ono Pharmaceutical Co stock appears to be overvalued.
The current stock price of 円2,428.00 is trading 8.4% above its estimated GF Value™ of 円2,240.58.
GuruFocus considers Ono Pharmaceutical Co to be Fairly Valued.
Key valuation signals for TSE:4528:
PB Ratio: 1.34 (36% below median its 10-year median of 2.10)
GF Value™: 円2,240.58 vs. price of 円2,428.00 (8.4% above fair value)
Industry Position: 29.8% below the Drug Manufacturers median (#321 of 925)
No single metric tells the full story. See the TSE:4528 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ono Pharmaceutical Co Ltd is a drug manufacturer with a focus on drug discovery in areas of unmet medical needs. The vast majority of the company's revenue is derived from its circulatory and respiratory drugs, followed by its metabolic drugs and vitamins. The company also reports revenue derived from royalties. The bulk of the company's sales is generated in Japan, followed by the rest of Asia and Europe.
89GF Score
Get the complete analysis for TSE:4528
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4528 has been successfully added to your 
